Somapacitan
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Somapacitan: From Growth Hormone Deficiency to Allergic Asthma
One-Sentence Summary
Somapacitan is a long-acting, albumin-binding recombinant human growth hormone derivative, marketed in Singapore as an injectable pen under the brand name SOGROYA. The TxGNN model predicts it may be effective for allergic asthma, but no clinical trials and no publications currently support this direction. This is a model-based prediction only, with no mechanistic or clinical evidence behind it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data compiled for this report (the drug is a long-acting growth hormone product) |
| Predicted New Indication | Allergic asthma |
| TxGNN Prediction Score | 95.73% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Somapacitan is known to be a long-acting growth hormone derivative that acts through the growth hormone receptor and the IGF-1 axis.
No direct link between this pathway and allergic airway inflammation (Th2/IgE pathways) has been established. The high TxGNN score reflects proximity in a knowledge graph, not demonstrated biology. Growth hormone and IGF-1 have reported immune-modulating effects, but their relevance to asthma remains speculative.
The other top predictions have similar problems. They include intrinsic asthma, rare COL4A1-related vascular disorders, RAAS-blocker-induced angioedema, gout, autoimmune hemolytic anemia, diabetic nephropathy, asthma-related susceptibility traits and a GPI-anchor biosynthesis disorder. None has trials or literature in the compiled data. For diabetic nephropathy and gout, growth hormone augmentation could potentially be harmful rather than beneficial.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17216P | SOGROYA Solution for Injection in Pre-filled Pen 5mg/1.5ml | Injection, solution | Not listed in the compiled data |
| SIN17217P | SOGROYA Solution for Injection in Pre-filled Pen 10mg/1.5ml | Injection, solution | Not listed in the compiled data |
| SIN17218P | SOGROYA Solution for Injection in Pre-filled Pen 15mg/1.5ml | Injection, solution | Not listed in the compiled data |
All three registrations are valid single-ingredient products from Novo Nordisk A/S.
Safety Considerations
- Drug Interactions: 100 interactions were identified, and the 20 reviewed here are all rated Moderate. They fall mainly into these groups:
- Antidiabetic agents: acarbose, albiglutide, alogliptin, metformin, pioglitazone, canagliflozin, chlorpropamide, dapagliflozin, saxagliptin
- Corticosteroids: hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide
- Acid suppressants: rabeprazole, omeprazole
- Other agents: aprepitant, clarithromycin, dolasetron, dronabinol
The antidiabetic interactions are consistent with growth hormone's effects on glucose metabolism. The corticosteroid interactions matter for any asthma use, since steroids are common in asthma care.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score (Evidence Level L5). There are no clinical trials or publications, and no plausible mechanism linking growth hormone receptor signaling to allergic asthma. Asthma is also an established indication area with effective, well-characterized therapies, so there is no clear unmet need that this drug would address.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA, which are required for safety screening
- Detailed mechanism of action data
- Preclinical or mechanistic evidence for growth hormone/IGF-1 effects on allergic airway inflammation
- A literature search for any observational data on growth hormone therapy and asthma outcomes
- Assessment of the metabolic and glucose-related safety profile in an asthma population, including interactions with corticosteroids
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.